Improved Disease on NaF-PET/CT in a 66-Year-Old Male with mCRPC who Had a PSA response to Docetaxel (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Improved Disease on NaF-PET/CT in a 66-Year-Old Male with mCRPC who Had a PSA response to Docetaxel

Caption

From a baseline PSA of 10.3, the PSA went down to 0.05 at 6 months and less than 0.01 at 12 months. Sequential NaF-PET/CT scans showed a significant decrease in uptake in the right pelvic skeletal lesion. Image intensities were equally adjusted.

Credit

M. Liza Lindenberg, MD, Center for Cancer Research, National Cancer Institute

Usage Restrictions

Please use title, caption and credit

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.